In high-risk T2DM, canagliflozin reduced CV events regardless of baseline renal function.

Herrington WG., Zhu D., Haynes R.

DOI

10.7326/ACPJ201902190-015

Type

Other

Publication Date

19/02/2019

Volume

170

Keywords

Canagliflozin, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Kidney, Sodium-Glucose Transporter 2 Inhibitors

Permalink Original publication